Kerendia for Heart Disease
Yes, Kerendia (finerenone) is FDA-approved for treating heart disease—specifically for reducing cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure with left ventricular ejection fraction (LVEF) ≥40%. 1
Primary Indications
Kerendia has two distinct FDA-approved indications:
Chronic kidney disease (CKD) associated with type 2 diabetes: To reduce sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure 1
Heart failure with LVEF ≥40%: To reduce cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults—regardless of diabetes or CKD status 1
Evidence for Heart Failure
The FINEARTS-HF trial established finerenone's efficacy in heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF), demonstrating a 13% reduction in the composite endpoint of cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure (12.4% vs 14.2%; HR 0.87, P=0.03). This benefit was primarily driven by a 29% reduction in heart failure hospitalizations (3.2% vs 4.4%; HR 0.71) 2.
The cardiovascular benefits extend across the spectrum of kidney function, with consistent effects regardless of baseline eGFR or albuminuria status 3. Importantly, patients with heart failure with reduced ejection fraction were excluded from trials, so finerenone is specifically indicated for LVEF ≥40% 2.
Dosing for Heart Failure vs CKD
The dosing differs between indications 1:
For Heart Failure (LVEF ≥40%):
- eGFR ≥60 mL/min/1.73m²: Target dose 40 mg once daily
- eGFR 25-59 mL/min/1.73m²: Target dose 20 mg once daily
- eGFR <25 mL/min/1.73m²: Initiation not recommended
For CKD with Type 2 Diabetes:
- eGFR ≥60 mL/min/1.73m²: Start 20 mg once daily
- eGFR 25-59 mL/min/1.73m²: Start 10 mg once daily, titrate to 20 mg
- eGFR <25 mL/min/1.73m²: Initiation not recommended
Clinical Positioning
For patients with CKD and type 2 diabetes, the 2024 KDIGO guidelines recommend finerenone as a nonsteroidal MRA for adults with eGFR >25 mL/min/1.73m², normal serum potassium, and albuminuria (>30 mg/g) despite maximum tolerated RAS inhibitor therapy 4. The pooled FIDELITY analysis (13,171 patients) showed a 23% reduction in composite kidney outcomes and a 14% reduction in cardiovascular events 2.
For patients with heart failure (LVEF ≥40%), finerenone provides benefits independent of diabetes or CKD status 3, 5. The 2025 ADA guidelines note that finerenone can be used interchangeably or in combination with SGLT2 inhibitors for cardiorenal protection 2.
Critical Safety Considerations
Hyperkalemia is the primary concern, occurring in approximately 10.8% of patients vs 5.3% with placebo, though only 1.2% discontinued due to hyperkalemia in trials 2.
Mandatory Monitoring Protocol 4, 6, 1:
Before initiation:
- Serum potassium must be ≤5.0 mEq/L (FDA label) or ≤4.8 mEq/L (trial protocols)
- Measure eGFR
After initiation:
- Check potassium and eGFR at 4 weeks
- Then monitor every 4 months during stable therapy
- Check 4 weeks after any dose adjustment
Dose adjustment based on potassium:
- K+ ≤4.8 mEq/L: Continue or uptitrate dose
- K+ 4.9-5.5 mEq/L: Continue current dose, monitor closely
- K+ >5.5 mEq/L: Withhold finerenone, address hyperkalemia, restart at 10 mg when K+ ≤5.0 mEq/L
Combination Therapy
Finerenone demonstrates complementary effects when combined with SGLT2 inhibitors, with preserved efficacy and acceptable safety 2, 5, 7. The 2024 KDIGO guidelines explicitly state that nonsteroidal MRAs may be added to RAS inhibitors and SGLT2 inhibitors for treatment of type 2 diabetes and CKD 4.
The choice between SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone should be based on:
- SGLT2 inhibitors: First-line for most patients with CKD or heart failure
- Finerenone: Add-on therapy for persistent albuminuria despite RAS inhibition, or for heart failure with LVEF ≥40%
- GLP-1 receptor agonists: Prioritize for patients with obesity or inadequate glycemic control
Common Pitfalls to Avoid
- Do not confuse with steroidal MRAs (spironolactone, eplerenone)—finerenone has distinct pharmacology and indications 8, 5
- Do not use in heart failure with reduced ejection fraction (LVEF <40%)—these patients were excluded from trials 2
- Do not initiate with potassium >5.0 mEq/L—this is an absolute contraindication 1
- Do not skip the 4-week potassium check—this is when hyperkalemia most commonly manifests 4, 6
- Do not use the same dosing for heart failure and CKD—target doses differ by indication 1